Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis

Breast Cancer Research and Treatment
Jieqiong LiuLisa K Jacobs

Abstract

Estrogen receptor (ER)-positive breast cancer patients treated with tamoxifen are known to have an elevated risk of subsequent endometrial cancer. However, it is unclear if ER-negative patients also have a higher risk of endometrial cancer. This population-based study aims to evaluate whether breast cancer patients with distinctive ER and PR status possess differential risks in developing delayed endometrial malignancy. Data were obtained from the Surveillance, Epidemiology, and End Results program (1992-2009). Standardized incidence ratio (SIR) was calculated as the observed cases of endometrial cancers among breast cancer survivors compared with the expected cases in the general population. Data were stratified by latency periods, race, age, and calendar year of breast cancer diagnosis. We identified 2044 patients who developed a second primary endometrial cancer among 289,933 breast cancer survivors. The overall SIRs for subsequent endometrial cancers were increased in all of the four subtypes (ER+PR+, ER+PR-, ER-PR+, and ER-PR-) of breast cancer. SIR was increased for all latency periods except for the initial 6-11 months after breast cancer diagnosis. Stratifying by age of diagnosis, elevated SIRs in all ER/PR groups were ...Continue Reading

References

Feb 19, 1994·Lancet·F E van LeeuwenF W Diepenhorst
Jun 19, 1996·Journal of the National Cancer Institute·R E CurtisJ F Fraumeni
Oct 8, 1999·Journal of the National Cancer Institute·L BernsteinL Ford
Feb 28, 2002·Cancer Letters·Hee Joon KangDong Young Noh
Sep 19, 2002·Journal of the National Cancer Institute·Deborah ThompsonUNKNOWN Breast Cancer Linkage Consortium
Mar 3, 2005·Journal of the National Cancer Institute·Anthony J SwerdlowUNKNOWN British Tamoxifen Second Cancer Study Group
Mar 15, 2005·American Journal of Clinical Pathology·Mehrdad NadjiAzorides R Morales
Oct 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Xiaojiang CuiAdrian V Lee
Dec 27, 2006·Pathology Oncology Research : POR·Jawad KianiShahid Pervez
Sep 19, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Emad A RakhaIan O Ellis
Jan 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leen De MaeyerPatrick Neven
Feb 28, 2008·Breast Cancer Research and Treatment·Sandra M SwainPatricia A Ganz
Mar 8, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael SchaapveldFlora E van Leeuwen
Jun 4, 2010·The New England Journal of Medicine·Sandra M SwainNorman Wolmark
Jan 4, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sara J SchonfeldWilliam F Anderson
Apr 9, 2013·Gynecologic Oncology·Yakir SegevUNKNOWN Hereditary Breast Cancer Study Group
Jan 31, 2014·Breast Cancer Research and Treatment·Kristin N AndersonMaria Elena Martinez
Mar 29, 2014·Breast Cancer Research and Treatment·Jianli ZhaoFengxi Su
Jun 7, 2014·Gynecologic Oncology·William M BurkeUNKNOWN Society of Gynecologic Oncology Clinical Practice Committee
Jul 11, 2014·American Journal of Epidemiology·Agnès FournierNathalie Chabbert-Buffet
Aug 5, 2014·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·C NgôUNKNOWN Gynecological Cancer Study Group of Institut Curie

❮ Previous
Next ❯

Citations

Mar 20, 2019·International Journal of Clinical Oncology·Jin-Li WeiZhi-Min Shao
Jan 4, 2020·Breast Cancer Research and Treatment·Akemi T WijayabahuLusine Yaghjyan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Cancer Disparities

Cancer disparities refers to differences in cancer outcomes (e.g., number of cancer cases, related health complications) across population groups.